TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures

PLoS ONE

Volumn 12, Issue 9, 2017, Pages

  Lustri, Anna Maria ^a   Di Matteo, Sabina ^a   Fraveto, Alice ^a   Costantini, Daniele ^a   Cantafora, Alfredo ^a   Napoletano, Chiara ^a   Bragazzi, Maria Consiglia ^a   Giuliante, Felice ^b   De Rose, Agostino M ^b   Berloco, Pasquale B ^a   Grazi, Gian Luca ^c   Carpino, Guido ^d   Alvaro, Domenico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CASEIN KINASE II; CATENIN; CYTOKERATIN 19; FLUORESCEIN ISOTHIOCYANATE; GALUNISERTIB; HISTONE H2AX; LIPOCORTIN 5; NERVE CELL ADHESION MOLECULE; SILMITASERTIB; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; 5-(3-CHLOROPHENYLAMINO)BENZO(C)(2,6)NAPHTHYRIDINE-8-CARBOXYLIC ACID; LY-2157299; NAPHTHYRIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; CORRELATIONAL STUDY; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MTS ASSAY; PRIMARY CELL CULTURE; PRIMARY CELL LINE; PROTEIN EXPRESSION; TGF BETA SIGNALING; WOUND HEALING ASSAY; BILE DUCT CARCINOMA; CANCER STEM CELL; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG RESISTANCE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WOUND HEALING;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHOLANGIOCARCINOMA; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NAPHTHYRIDINES; NEOPLASTIC STEM CELLS; PRIMARY CELL CULTURE; PYRAZOLES; QUINOLINES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 85028921091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183932     Document Type: Article

References (41)

1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P et al., Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepa-tol. 2016; 13:261–280. https://doi.org/10.1038/nrgastro.2016.51 PMID: 27095655
2. Cardinale V, Carpino G, Reid LM, Gaudio E, Alvaro D. Cholangiocarcinoma: a cancer in search of the right classification. Hepatology. 2012; 56:1585–1586.
3. Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenbergen W, Verslype C, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012; 55: 1876–1888. https://doi.org/10.1002/hep.25595 PMID: 22271564
4. Cardinale V, Renzi A, Carpino G, Torrice A, Bragazzi MC, Giuliante F et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol. 2015; 185:1724–39. https://doi.org/10.1016/j.ajpath.2015.02.010 PMID: 25892683
5. Fraveto A, Cardinale V, Bragazzi MC, Giuliante F, De Rose AM, Grazi GL et al.Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.PLoS One. 2015; 10:1–19.
6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119:1420–1428. https://doi.org/10.1172/JCI39104 PMID: 19487818
7. Thiery J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442–454. https://doi.org/10.1038/nrc822 PMID: 12189386
8. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate.2002; 52: 253–263. https://doi.org/10.1002/pros.10088 PMID: 12210485
9. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003; 15:740–746. PMID: 14644200
10. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178–96. https://doi.org/10.1038/nrm3758 PMID: 24556840
11. Padua D, Massagué J. Roles of TGFβ in metastasis. Cell Research. 2009; 19:: 89–102. https://doi.org/10.1038/cr.2008.316 PMID: 19050696
12. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells. 2002; 7:1191–1204. PMID: 12485160
13. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113:685–700. PMID: 12809600
14. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998; 67:753–791. https://doi.org/10.1146/annurev.biochem.67.1.753 PMID: 9759503
15. Sato Y, Itatsu K H, Ikeda H, Kakuda Y, Shimomura S, Ren X S et al. Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-1/Snail Activation Aggravates Invasive Growth of Cholangiocarcinoma. Am J Pathol. 2010; 177: 141–152. https://doi.org/10.2353/ajpath.2010.090747 PMID: 20489148
16. Duangkumpha K, Techasen A, Loilome W, Numwat N, Thaman R, Khuntikeo N et al. BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma. Tumour Biol. 2014; 35: 9667–9676. https://doi.org/10.1007/s13277-014-2246-9 PMID: 24969562
17. Chen Y, Ma L, He Q, Zhang S, Zhang C, Jia W.TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biological Research. 2015; 48:1–5. https://doi.org/10.1186/0717-6287-48-1
18. Kim J, Hwan Kim S. CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelialto- Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS One. 2013; 8: 1–13.
19. Nevi L, Carpino G, Costantini D, Cardinale V, Riccioni O, Di Matteo S et al. Hyaluronan coating improves liver engraftment of transplanted human biliary tree stem/progenitor cells. Stem Cell Research & Therapy. 2017; 8:1–14.
20. Iuso D, Czernik M, Di Egidio F, Sampino S, Zacchini F, Bochenek M, et al., Genomic Stability of Lyophi-lized Sheep Somatic Cells before and after Nuclear Transfer. Plos one. 2013; 8:1–9.
21. Cardinale V, Renzi A, Carpino G, Torrice A, Bragazzi M. C., Giuliante F et al., Profiles of Cancer Stem Cell Subpopulations in Cholangiocarcinomas. The American Journal of Pathology. 2015; 185:1724–1739. https://doi.org/10.1016/j.ajpath.2015.02.010 PMID: 25892683
22. Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP et al., Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.Oncotarget. 2014; 15:7328–41.
23. Takeishi Y, Ohashi E, Ogawa K, Masai H, Obuse C and Tsurimoto T: Casein kinase 2-dependent phosphorylation of human Rad9 mediates the interaction between human Rad9-Hus1-Rad1 complex and TopBP1. Genes Cells. 2010; 15: 761–771. https://doi.org/10.1111/j.1365-2443.2010.01418.x PMID: 20545769
24. Olsen BB, Issinger OG and Guerra B: Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells. Oncogene. 2010; 29: 6016–6026. https://doi.org/10.1038/onc.2010. 337 PMID: 20711232
25. Ström CE, Mortusewicz O, Finch D, Parsons JL, Lagerqvist A, Johansson F et al. CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair. 2011; 10: 961–969. https://doi.org/10.1016/j.dnarep.2011.07.004 PMID: 21840775
26. Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao XM et al. Transforming growth factor-β1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Letters. 2014; 354: 320–328. https://doi.org/10.1016/j.canlet.2014.08.030 PMID: 25194504
27. Lanier MH, Kim T, Cooper JA. CARMIL2 is a novel molecular connection between vimentin and actin essential for cell migration and invadopodia formation. Molecular Biology of the Cell. 2015; 26: 4577–4588. https://doi.org/10.1091/mbc.E15-08-0552 PMID: 26466680
28. Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao XM et al. Transforming growth factor-β1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Letters. 2014; 354: 320–328. https://doi.org/10.1016/j.canlet.2014.08. 030 PMID: 25194504
29. Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z. MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer Int. J. Biol. Sci. 2015; 11: 411–422. https://doi.org/10.7150/ijbs.10745 PMID: 25798061
30. Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME et al.,. miR-579-3p controls melanoma progression and resistance to target therapy.Proc Natl Acad Sci U S A. 2016; 113:E5005–5013. https://doi.org/10.1073/pnas.1607753113 PMID: 27503895
31. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M et al. Exprerssion of growth factor receptors andtargeting of EGFR in cholangiocarcinomacell lines. BMC Cancer. 2010; 10: 1471–2407.
32. So KS, Rho JK, Choi YJ, Kim SY, Choi CM, Chun YJ et al. AKT/mTORDown-regulation by CX-4945,a CK2 Inhibitor, Promotes Apoptosis in Chemorefractory Non-small Cell Lung Cancer Cells. Anticancer Research. 2015; 35:1537–1542 PMID: 25750308
33. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al., Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008; 68: 9479–9487. https://doi.org/10.1158/0008-5472.CAN-08-1643 PMID: 19010923
34. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen L H, Klümpen H-J et al., Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma(ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015; 15:1–8. https://doi.org/10.1186/1471-2407-15-1
35. Dituri F, Mazzocca A, Juan Peidro‘F, Papappicco P, Fabregat I, De Santi F et al.,. Differential Inhibition of the TGF-b Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-b Receptor Type II. Plos one. 2013; 8:1–15.
36. Kothari A N, Mi Z, Zapf M and Kuo P C. Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clinical and Translational Medicine. 2014; 3:1–4. https://doi.org/10.1186/2001-1326-3-1
37. Kim J, Hwan Kim S. CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells. PLoS One. 2013 4; 8:1–8.
38. Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L.Protein kinase CK2a is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. Journal of Translational Medicine. 2011; 9:1–11
39. Gray GK, McFarland BC, Rowse AL, Gibson SA, Benveniste EN.Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.Oncotarget. 2014; 5:6484–6496. https://doi.org/10.18632/oncotarget.2248 PMID: 25153725
40. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et a. Protein kinase CK2 phosphorylates and upregulates Akt/PKB.Cell Death and Differentiation. 2005; 12: 668–677. https://doi.org/10.1038/sj.cdd.4401604 PMID: 15818404
41. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O’Brien SE et al., CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70:10288–98. https://doi.org/10.1158/0008-5472.CAN-10-1893 PMID: 21159648